ERBB2 and breast cancer: Similarly, in a retrospective analysis of a prospective randomized trial in HR+ breast cancer in which postmenopausal patients with early stage HR+/HER2- breast cancer were randomized to tamoxifen treatment or no adjuvant therapy, it was found that tumors with high CD8+ T cell infiltrates were associated with increased recurrence risk (36).